Islet antoantibodies as potential markers for disease recurrence in clinical islet transplantation

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 5, 2000, Pages 328-333

  Jaeger, C ^a   Brendel, M D ^a   Eckhard, M ^a   Bretzel, R G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Alloimmunity; Autoantibodies; Autoimmunity; Disease recurrence; Islet transplantation

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN; PREDNISOLONE; BIOLOGICAL MARKER;

ADULT; ALLOGRAFT; ANTIBODY PRODUCTION; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; DIABETES MELLITUS; IMMUNOLOGY; PANCREAS ISLET;

AUTOANTIBODIES; BIOLOGICAL MARKERS; DIABETES MELLITUS; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; RECURRENCE;

EID: 0033626339     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8125     Document Type: Review

References (32)

1. Atkinson MA, Maclaren NK: The pathogenesis of insulin dependent diabetes. N Engl J Med 331: 1428-1436, 1994
2. Bach JF: Insulin dependent diabetes as an autoimmune disease. Endocr Rev 14: 516-542, 1994
3. Bartlett ST, Chin T, Dirden B, Quereshi A, Hadley G: Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: evidence of donor chimerism. Surgery 118: 392-397, 1995
4. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazo GF, Gale EAM, Bosi E: Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38: 816-822, 1996
5. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E: Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes 49: 218-224, 2000
6. Brooks-Worrell BM, Peterson KP, Peterson CM, Palmer JP, Jovanovic L: Reactivation of type 1 diabetes in patients receiving human fetal pancreatic tissue transplants without immunosuppression. Transplantation 69: 166-172, 2000
7. Bretzel RG: Biological alternatives to insulin therapy. Exp Clin Endocrinol Diabetes 107 (Suppl 2): 839-843, 1999
8. Bretzel RG, Brandhorst D, Brandhorst H, Eckhard M, Ernst W, Friemann S, Rau W, Weimar B, Rauber K, Hering BJ, Brendel MD: Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 77: 140-143, 1999
9. Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574-1582, 1988
10. De Filippo G, Carel JC, Boitard C, Bougneres PF: Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45: 101-104, 1996
11. Esmatjes E, Rodriguez-Villar C, Ricart MJ, Casamitjana R, Martorell J, Sabater L, Astudillo E, Fernandez-Cruz L: Recurrence of immunological markers for type-1 (insulin-dependent) diabetes mellitus in immunosuppressed patients after pancreas transplantation. Transplantation 66: 128-131, 1998
12. Giannoukakis M, Rudert WA, Robbins PD, Trucco M: Targeting autoimmune diabetes with gene therapy. Diabetes 48: 2107-2121, 1999
13. Hering BJ, Ricordi C: Results, research priorities, and reasons for optimism: Islet transplantation for patients with type 1 diabetes. Graft 2: 12-27, 1999
14. Jaeger C, Allendörfer J, Hatziagelaki E, Dyrberg T, Bergis KH, Federlin K, Bretzel RG: Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual betacell function, neuropathy or HLA-DR status. Horm Metab Res 29: 510-515, 1997
15. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG: Progressive islet graft failure occurs significantly earlier in autoantibody positive than in autoantibody negative IDDM recipients of intrahepatic islet allografts. Diabetes 46: 1907-1910, 1997
16. Jaeger C, Hatziagelaki E, Stroedter A, Becker F, Scherer S, Petzoldt R, Federlin K, Bretzel RG: The Giessen-Bad Oeynhausen familiy study: Improved prediction of type-1 diabetes in a low incidence population of relatives using combinations of islet autoantibodies in a dual step model. Exp Clin Endocrinol Diabetes 107: 496-505, 1999
17. Jaeger C, Hering BJ, Dyrberg T, Federlin K, Bretzel RG: Islet cell antibodies and GAD 65 antibodies in IDDM patients undergoing kidney and islet after kidney transplantation. Transplantation 62: 424-426, 1996
18. Mandrup-Poulsen T, Molvig J, Andersen HU, Helqvist S, Spinas GA, Munck M the Canadian-European Randomized Control Trial Group: Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. Diabetes 39: 204-210, 1990
19. Petersen JS, Dyrberg T, Karlsen AE, Molvig J, Michelsen B, Nerup J, Mandrup-Poulsen T the Canadian-European Randomized control Trial Group: Glutamic acid decarboxylase (GAD 65) autoantibodies in prediction of β-cell function and remission in recent-onset IDDM after cyclosporin treatment. Diabetes 43: 1291-1296, 1994
20. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, Claas FHJ, de Vries RRP: Auto- and alloimmune reactivity to human islet allografts transplanted into type-1 diabetic patients. Diabetes 48: 484-490, 1999
21. Roll U, Ziegler A: Combined antibody screening for improved prediction of IDDM-Modern strategies. Exp Clin Endocrinol Diabetes 105: 1-14, 1997
22. Savola K, Sabbah E, Kulmala P, Vähäsalo P, Honen J, Knip M: Autoantibodies associated with type-1 diabetes mellitus persist after diagnosis in children. Diabetologia 41: 1293-1297, 1998
23. Schwartz RS: The new immunology-the end of immunosuppressive drug therapy? N Engl J Med 340: 1754-1756, 1999
24. Sibley RK, Sutherland DER, Goetz F, Michael AF: Recurrent diabetes mellitus in the pancreas iso and allograft: A light and electron microscopic and immunohisto-chemical analysis of four cases. Lab Invest 53: 132-144, 1985
25. Stegall MD, Lafferty KJ, Kam I, Gill RG: Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation 63: 1272-1274, 1996b
26. Stegall MD, Lobermann Z, Ostrowska A: Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody. J Surg Res 64: 156-160, 1996a
27. Sundkvist G, Tyden G, Karlsson FA, Bolinder J: Islet autoimmunity before and after pancreas transplantation in patients with type-1 diabetes mellitus. Diabetologia 41: 1532-1534, 1998
28. Terada M, Salzer M, Lennartz K, Mullen F: The effect of H2 compatibility on pancreatic beta cell survival in the nonobese diabetic mouse. Transplantation 45: 622-627, 1988
29. Thivolet Ch, Abou-Amara S, Martin X, Lefrancois N, Petruzzo P, McGregor B, Bosshard S, Dubernard JM: Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation. Transplantation 69: 99-103, 2000
30. Tyden G, Reinholt FP, Sundkvist G, Bolinder J: Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 335: 860-863, 1996
31. Wang Y, McDuffie M, Nomikos IN, Hao L, Lafferty KJ: Effect of cyclosporin on immunologically mediated diabetes in nonobese diabetic mice. Transplantation 46: 1018-1068, 1988
32. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, Hirasawa K, Sherwin RS, Jun HS: Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 284: 1183-1187, 1999